Amneal Pharmaceuticals (AMRX) Cost of Revenue (2017 - 2026)

Amneal Pharmaceuticals has reported Cost of Revenue for 10 years, with the latest figure at $461.7 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 5.35% year-over-year to $461.7 million in Q2 2026; TTM through Jun 2026 was $1.9 billion, a 6.38% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 7.44% from the prior year.
• Cost of Revenue was $461.7 million for Q2 2026 at Amneal Pharmaceuticals, up from $402.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $517.1 million in Q4 2025, with the low at $323.1 million in Q1 2022.
• Average Cost of Revenue over 5 years is $419.1 million, with a median of $424.1 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Cost of Revenue advanced 19.21% in 2024, then retreated 8.45% in 2026.
• Over 5 years, Cost of Revenue stood at $394.4 million in 2022, then climbed by 8.31% to $427.2 million in 2023, then gained by 9.48% to $467.6 million in 2024, then gained by 10.58% to $517.1 million in 2025, then fell by 10.72% to $461.7 million in 2026.
• The last three Cost of Revenue figures came in at $461.7 million (Q2 2026), $402.4 million (Q1 2026), and $517.1 million (Q4 2025), per Business Quant data.